Correspondingly, the prognosis of tumor patients with high MALAT1 expression is also poor, which also indicates that MALAT1 expression level can be a potential biomarker for stage II/III CRC patients [12]. This evidence concerns the gene MALAT1 and colorectal carcinoma.